image: An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide — a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care. The substudy, co-led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, was presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain and published today in European Urology.
Credit: Dana-Farber Cancer Institute
BOSTON, October 24, 2026 – An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide — a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.
The substudy, co-led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, was presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain and published today in European Urology. Alberto Briganti, MD, PhD, Professor of Urology at Vita-Salute San Raffaele University in Milan, Italy, presented the data at ESMO.
Previous Dana-Farber research led by Taplin, presented earlier this year at the American Society for Clinical Oncology (ASCO) Annual Meeting and published in The New England Journal of Medicine, found that apalutamide plus androgen-deprivation hormone therapy (ADT) prior to and after surgery showed significant promise for patients with high-risk localized prostate cancer. Patients treated with the apalutamide plus hormone therapy regimen were nine times more likely to have little to no cancer present at surgery, reduced the risk of metastases or death by 20% and delayed subsequent therapy by 33 months compared to ADT alone.
The substudy compared the novel perioperative approach to standard of care, radical prostatectomy alone.
“Following the presentation of the PROTEUS results at ASCO, an important question remained: how does this regimen compare with standard of care prostatectomy? Addressing that question is essential to understanding the full clinical significance of these findings and determining how they can best inform treatment decisions for patients with high-risk localized prostate cancer,” said Taplin. “This substudy demonstrated superior efficacy of perioperative apalutamide plus ADT over radical prostatectomy alone in high-risk localized/locally advanced prostate cancer, reinforcing the PROTEUS main study findings.”
PROTEUS substudy is a 1:3 randomized trial that included 408 patients with newly diagnosed high-risk localized or locally advanced prostate cancer designed to compare apalutamide plus ADT before and after surgery to standard of care radical prostatectomy. Apalutamide is approved for use in metastatic castration-sensitive prostate cancer and for nonmetastatic castration-resistant prostate cancer.
Participating patients received apalutamide plus ADT for 6 months before and after radical prostatectomy with pelvic lymph-node dissection or standard or prostatectomy alone. The study’s primary endpoint was event-free survival (events included PSA, clinical, PSMA-PET or conventional imaging relapse). After a median follow-up of 37.8 months, the combination of apalutamide plus ADT and prostatectomy resulted in a 62 percent improvement in event-free survival and a 51 percent reduced risk of metastasis or death. The combination reduced the risk of starting a subsequent therapy by 71 percent, and 50 percent fewer patients started subsequent therapy by 3 years.
Side effects were consistent with data from previously reported studies.
“Combined evidence from the main and substudy support perioperative apalutamide plus ADT and prostatectomy as a potential treatment of choice in patients fit for surgery and systemic therapy,” said Taplin.
Funding: Johnson & Johnson
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is a global leader in cancer research and care, with a mission to reduce the burden of cancer through scientific discovery, clinical excellence, education, community engagement and advocacy. Dana-Farber is dedicated to a unique and equal balance of cancer research and care, offering more than 1,200 clinical trials and translating the results of discovery into new treatments for patients locally and around the world. U.S. News & World Report recognized Dana-Farber Brigham Cancer Center as the Best Hospital for Cancer in Massachusetts and number three in the nation, and Dana-Farber Boston Children’s Cancer and Blood Disorders Center as the Best Children’s Hospital for Cancer in the country, making Dana-Farber the only hospital in the country among the top three for both adult and pediatric cancer care. It is a federally designated Comprehensive Cancer Center and a principal teaching affiliate of Harvard Medical School.
###
Media Contact
Victoria Warren
Victoria_Warren@dfci.harvard.edu
617-939-5531
Journal
European Urology
Article Title
Radical Prostatectomy Alone in Patients with High-risk Localized or Locally Advanced Prostate Cancer from the PROTEUS Substudy
Article Publication Date
24-Oct-2026